IP Library Granted Patent US 9,120,807
Granted Patent B2
US 9,120,807 · App. 12/678,378 · Granted Sep 1, 2015

Thienopyrimidine compounds

Inventors: Allan Jordan (Winnersh, GB); Simon Bedford (Winnersh, GB); Klenke Burkhard (Winnersh, GB); Ian Yule (Winnersh, GB); Karine Poullennec (Winnersh, GB)
Assignee: Vernalis (R&D) Ltd.
C07D495/04A61K31/519
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,120,807
App. No.
12/678,378
Granted
Sep 1, 2015
Kind
B2
Abstract

Compounds of formula (I) are A 2B receptor antagonists, wherein R 1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring; R 2 and R 3 are independently selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl-(C 1 -C 6 )-alkyl, aryl-(C 1 -C 6 )-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C 1 -C 6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl; or R 2 and R 3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R 4 is C 1 -C 3 alkyl, C 2 -C 3 alkenyl, —N(—R 5 )—R 6 , or optionally substituted heteroarylmethylamino; and R 5 and R 6 are independently selected from hydrogen or C 1 -C 3 alkyl; or R 5 and R 6 taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered saturated ring.

Claims (37)

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:

wherein

R 1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring;

R 2 and R 3 are independently selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl-(C 1 -C 6 )-alkyl, aryl-(C 1 -C 6 )-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C 1 -C 6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl;

or R 2 and R 3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring;

R 4 is C 1 -C 3 alkyl, C 2 -C 3 alkenyl, —N(—R 5 )—R 6 , or optionally substituted heteroarylmethylamino; and

R 5 and R 6 are independently selected from hydrogen or C 1 -C 3 alkyl;

or R 5 and R 6 taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered saturated ring.

2. A compound as claimed in claim 1 wherein R 1 is an optionally substituted 5- or 6-membered heteroaryl ring.

3. A compound as claimed in claim 1 wherein R 1 is an optionally substituted 5-membered heteroaryl ring.

4. A compound as claimed in claim 1 wherein R 1 is optionally substituted thienyl.

5. A compound as claimed in claim 4 wherein R 1 is thienyl optionally substituted by fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, ethyl, hydroxyl, hydroxymethyl, or hydroxyethyl.

6. A compound as claimed in claim 1 wherein R 1 is thien-2-yl.

7. A compound as claimed in claim 1 wherein R 2 is hydrogen, or a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C 1 -C 6 alkylene chain and optionally substituted in the ring part thereof.

8. A compound as claimed in claim 7 wherein R 2 is hydrogen.

9. A compound as claimed in claim 7 wherein R 2 is an optionally substituted 5- or 6-membered monocyclic heteroaryl group linked via a C 1 -C 6 alkylene chain.

10. A compound as claimed in claim 7 wherein R 2 is a 5- or 6-membered monocyclic heteroaryl group linked via a C 1 -C 6 alkylene chain and optionally substituted in the ring part thereof by fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, ethyl, hydroxyl, hydroxymethyl, or hydroxyethyl.

11. A compound as claimed in claim 1 wherein R 3 is hydrogen, or a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C 1 -C 6 alkylene chain and optionally substituted in the ring part thereof.

12. A compound as claimed in claim 11 wherein R 3 is an optionally substituted 5- or 6-membered monocyclic heteroaryl group linked via a C 1 -C 6 alkylene chain.

13. A compound as claimed in claim 11 wherein R 3 is a 5- or 6-membered monocyclic heteroaryl group linked via a C 1 -C 6 alkylene chain and optionally substituted in the ring part thereof by fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, ethyl, hydroxyl, hydroxymethyl, or hydroxyethyl.

14. A compound as claimed in claim 1 wherein R 4 is amino.

15. A compound as claimed in claim 1 wherein R 4 is mono C 1 -C 3 alkylamino.

16. A compound as claimed in claim 15 wherein R 4 is methylamino.

17. A compound as claimed in claim 15 wherein R 4 is ethylamino.

18. A compound as claimed in claim 1 wherein R 4 is C 1 -C 3 alkyl.

19. A compound as claimed in claim 18 wherein R 4 is ethyl.

20. A compound of formula (II) or a pharmaceutically acceptable salt thereof:

wherein

R 1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring;

R 2 and R 3 are independently selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl-(C 1 -C 6 )-alkyl, aryl-(C 1 -C 6 )-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C 1 -C 6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl;

or R 2 and R 3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; and

R 4 is hydrogen or C 1 -C 3 alkyl.

21. A compound as claimed in claim 20 wherein R 1 is thien-2-yl.

22. A compound as claimed in claim 20 wherein R 2 is hydrogen and R 3 is pyrid-3-ylmethyl.

23. A compound as claimed in claim 20 wherein R 4 is hydrogen or methyl.

24. A pharmaceutical composition comprising a compound as claimed in claim 1 and a pharmaceutically acceptable carrier.

25. A compound as claimed in claim 1 wherein R 1 is thien-2-yl, R 2 is hydrogen, and R 3 is pyrid-3-ylmethyl.

Assignments (3)
CHANGE OF NAME Recorded Jan 24, 2022
From: VERNALIS DEVELOPMENT LIMITED
To: LIGAND UK DEVELOPMENT LIMITED
Reel/Frame 058738/0271 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2022
From: VERNALIS (R&D) LIMITED
To: VERNALIS DEVELOPMENT LIMITED
Reel/Frame 058822/0570 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2010
From: JORDAN, ALLAN; BEDFORD, SIMON; BURKHARD, KLENKE; YULE, IAN; POULLENNEC, KARINE
To: VERNALIS (R&D) LTD.
Reel/Frame 024564/0535 →
Priority Claims (1)
GB 0718434.4 · Sep 21, 2007 · national
Continuity (1)
Related Publication 20110118284A1 · May 19, 2011